专利检索 ap:("Frank Chavez" OR "Michael P. Curtis" OR "James P. Edwards" OR "Laurent Gomez" OR "Cheryl A. Grice" OR "Aaron M. Kearney" OR "Brad M. Savall") AND inv:"Aaron M. Kearney" 第 1 页

1.

发明授权
Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor 有权
标题翻译：组胺H4受体的苯并呋喃和苯并噻吩并嘧啶调节剂

公开(公告)号：US07576092B2

公开(公告)日：2009-08-18

申请号：US11827354

申请日：2007-07-10

申请人： Frank Chavez , Michael P. Curtis , James P. Edwards , Anne E. Fitzgerald , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Jing Liu , Neelakandha S. Mani , Brad M. Savall

发明人： Frank Chavez , Michael P. Curtis , James P. Edwards , Anne E. Fitzgerald , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Jing Liu , Neelakandha S. Mani , Brad M. Savall

IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D471/00 , C07D487/00 , C07D491/00

CPC分类号： C07D491/048 , C07D491/147 , C07D495/04 , C07D519/00

摘要： Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

摘要翻译： 描述了苯并呋喃和苯并噻吩并嘧啶化合物，其可用作H 4受体调节剂。这些化合物可用于治疗由H 4受体活性介导的疾病状态，病症和病症的药物组合物和方法，例如过敏，哮喘，自身免疫性疾病和瘙痒症。

2.

发明申请
Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor 有权

公开(公告)号：US20090325927A1

公开(公告)日：2009-12-31

申请号：US12496932

申请日：2009-07-02

申请人： Frank Chavez , Michael P. Curtis , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Brad M. Savall

发明人： Frank Chavez , Michael P. Curtis , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Brad M. Savall

IPC分类号： A61K31/496 , C07D491/048 , C07D405/14 , A61K31/551 , A61K31/397 , A61P37/00

CPC分类号： C07D491/048 , C07D491/147 , C07D495/04 , C07D519/00

摘要： Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

3.

发明授权
Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor 有权
标题翻译：组胺H4受体的苯并呋喃和苯并噻吩并嘧啶调节剂

公开(公告)号：US08030321B2

公开(公告)日：2011-10-04

申请号：US12496932

申请日：2009-07-02

申请人： Frank Chavez , Michael P. Curtis , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Brad M. Savall

发明人： Frank Chavez , Michael P. Curtis , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Brad M. Savall

IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D471/00 , C07D491/00

CPC分类号： C07D491/048 , C07D491/147 , C07D495/04 , C07D519/00

摘要： Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

摘要翻译： 描述了苯并呋喃和苯并噻吩并嘧啶化合物，其可用作H 4受体调节剂。这些化合物可用于治疗由H 4受体活性介导的疾病状态，病症和病症的药物组合物和方法，例如过敏，哮喘，自身免疫性疾病和瘙痒症。

4.

发明申请
Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor 有权
标题翻译：组胺H4受体的苯并呋喃和苯并噻吩并嘧啶调节剂

公开(公告)号：US20080015200A1

公开(公告)日：2008-01-17

申请号：US11827354

申请日：2007-07-10

申请人： Frank Chavez , Michael P. Curtis , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Brad M. Savall

发明人： Frank Chavez , Michael P. Curtis , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Brad M. Savall

IPC分类号： A61K31/519 , A61K31/4985 , A61P1/00 , A61P17/00 , A61P27/00 , A61P37/00 , A61P5/00 , A61P9/00 , C07D239/70 , C07D403/14

CPC分类号： C07D491/048 , C07D491/147 , C07D495/04 , C07D519/00

摘要： Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

摘要翻译： 描述了苯并呋喃和苯并噻吩并嘧啶化合物，其可用作H 4 S 5受体调节剂。这样的化合物可以用于治疗由H 4 S受体活性介导的疾病状态，病症和病症的药物组合物和方法，例如过敏，哮喘，自身免疫疾病和瘙痒症。

5.

发明授权
Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase 有权
标题翻译：芳基取代的桥连或稠合二胺作为白三烯A型调质剂

公开(公告)号：US08344008B2

公开(公告)日：2013-01-01

申请号：US13091498

申请日：2011-04-21

申请人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alexandro Santillán, Jr.

发明人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alexandro Santillán, Jr.

IPC分类号： A61K31/425

CPC分类号： C07D487/08 , C07D417/12 , C07D451/04 , C07D471/04 , C07D471/08 , C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

摘要翻译： 芳基取代的桥连或稠合二胺化合物，含有它们的药物组合物，以及使用该化合物和药物组合物用于白三烯A4水解酶（LTA4H或LTA4H）调节和治疗由LTA4H活性介导的疾病状态，障碍和病症的方法，例如过敏，哮喘，自身免疫性疾病，瘙痒炎，炎性肠病，溃疡性结肠炎和心血管疾病，包括动脉粥样硬化和预防心肌梗死。

6.

发明申请
Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase 有权
标题翻译：芳基取代的桥连或稠合二胺作为白三烯A4水解酶的调节剂

公开(公告)号：US20090111794A1

公开(公告)日：2009-04-30

申请号：US12291018

申请日：2008-10-30

申请人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillan, JR.

发明人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillan, JR.

IPC分类号： A61K31/55 , C07D277/68 , C07D263/54 , C07D487/08 , A61K31/423 , A61K31/4439 , A61P37/02 , A61K31/497 , A61K31/428 , C07D401/14 , C07D417/14

CPC分类号： C07D487/08 , C07D417/12 , C07D451/04 , C07D471/04 , C07D471/08 , C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

摘要翻译： 芳基取代的桥连或稠合二胺化合物，含有它们的药物组合物，以及使用该化合物和药物组合物用于白三烯A4水解酶（LTA4H或LTA4H）调节和治疗由LTA4H活性介导的疾病状态，障碍和病症的方法，例如过敏，哮喘，自身免疫性疾病，瘙痒炎，炎性肠病，溃疡性结肠炎和心血管疾病，包括动脉粥样硬化和预防心肌梗死。

7.

发明申请
Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase 有权
标题翻译：芳基取代的桥连或稠合二胺作为白三烯A4水解酶的调节剂

公开(公告)号：US20110263639A1

公开(公告)日：2011-10-27

申请号：US13091772

申请日：2011-04-21

申请人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillán, JR.

发明人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillán, JR.

IPC分类号： A61K31/46 , C12N9/99 , A61P29/00 , C07D451/04

CPC分类号： C07D487/08 , C07D417/12 , C07D451/04 , C07D471/04 , C07D471/08 , C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

摘要翻译： 芳基取代的桥连或稠合二胺化合物，含有它们的药物组合物，以及使用该化合物和药物组合物用于白三烯A4水解酶（LTA4H或LTA4H）调节和治疗由LTA4H活性介导的疾病状态，障碍和病症的方法，例如过敏，哮喘，自身免疫性疾病，瘙痒炎，炎性肠病，溃疡性结肠炎和心血管疾病，包括动脉粥样硬化和预防心肌梗死。

8.

发明申请
Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase 有权

公开(公告)号：US20110257153A1

公开(公告)日：2011-10-20

申请号：US13091498

申请日：2011-04-21

申请人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. Mcclure , Taraneh Mirzadegan , Alexandro Santillan, JR.

发明人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. Mcclure , Taraneh Mirzadegan , Alexandro Santillan, JR.

IPC分类号： A61K31/428 , C12N9/99 , C07D451/02 , A61K31/46 , A61K31/4995 , C07D487/04 , C07D471/04 , A61K31/437 , A61K31/4375 , A61K31/5377 , A61P29/00 , A61P17/00 , A61P11/06 , A61P1/00 , A61P9/10 , A61P17/02 , C07D487/08

CPC分类号： C07D487/08 , C07D417/12 , C07D451/04 , C07D471/04 , C07D471/08 , C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

9.

发明授权
Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase 有权

公开(公告)号：US08367719B2

公开(公告)日：2013-02-05

申请号：US13091772

申请日：2011-04-21

申请人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillán, Jr.

发明人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillán, Jr.

IPC分类号： A61K31/34

CPC分类号： C07D487/08 , C07D417/12 , C07D451/04 , C07D471/04 , C07D471/08 , C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.